



Imugene HER-Vaxx patent granted in US

- *Core US patent granted in world's largest pharmaceutical market*
- *Patent provides method of composition and method of use protection to 2030*

Melbourne, 8 October 2014: Australian biopharmaceutical company Imugene Limited (ASX:IMU) has received a Notice of Grant from the United States Patent and Trademark Office (USPTO) for Patent Application 13/389419 (granted patent no. 8,852,604) which protects its HER-Vaxx cancer immunotherapy, currently in development for gastric cancer.

The patent titled "Multiepitope Vaccine for HER2/Neu-associated Cancers" protects the method of composition and method of use of Imugene's HER-Vaxx for the generation of a therapeutic antibody response against HER-2/neu.

HER-Vaxx is a proprietary therapeutic cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu, the same biomarker targeted by the \$US6.9 billion per annum drug Herceptin®. HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase Ib/II study in gastric cancer.

Gastric or stomach cancer is the second most common cause of cancer-related death in the world and the fourth most commonly diagnosed cancer, with over 1,000,000 new cases diagnosed each year.

Contact :

Charles Walker
Chief Executive Officer
+61 450 446 990
cwalker[at]imugene.com

Paul A Hopper
Executive Chairman
+1 858 334 5820 (US)
+61 406 671 515 (Australia)
receptogen[at]earthlink.net

Media contact:

Rudi Michelson
Monsoon Communications
+61 3 9620 3333
rudim[at]monsoon.com.au

About Imugene: Imugene (ASX; IMU) is an immuno-oncology biopharmaceutical company developing HER2 +ve gastric and breast cancer immunotherapies. The Company's lead product is HER-Vaxx, a proprietary HER2 +ve cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase Ib/II study in gastric cancer. Imugene's corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria. For more information on Imugene, please visit www.imugene.com